Amit Kumar Das

Amit Kumar Das

Auto-generated profile, based on publicly available information

Amit Kumar Das

Department of Pharmaceutics, NETES Institute of Pharmaceutical Science, NEMCARE Group of Institutions, Mirza, Assam, 781125, India

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in Discover Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
SSSaruma Sahin
Saruma Sahin
SSSwapnaneel Sarma
Swapnaneel Sarma
ADAnisa Das
Anisa Das
BBBitopan Baishya
Bitopan Baishya
ADAmit Kumar Das
Amit Kumar Das
MDManoj Kumar Deka
Manoj Kumar Deka
Background Spanlastics are elastic nanovesicles designed to improve drug solubility, stability, and penetration across ocular barriers, which makes them ideal for delivering linezolid to the eye. The paper discusses in detail linezolid ocular delivery and its therapeutic efficiencies. Main body Treatment conditions that are associated with optics and, in particular, with antibiotic-resistant bacteria represent a major reason for therapeutic limitations that develop through limited and conventional delivery systems of drugs. One synthetic antibiotic like linezolid, has been widely used for excellent efficacy against infections caused by methicillin-resistant Staphylococcus aureus, among many gram-positive bacteria, and hence, there is an opportunity for its use as an ocular agent of therapy. However, poor ocular bioavailability, limited penetration to deeper eye tissues, and the requirement for frequent administrations have often been associated with medical efficacy. Novel tactics for transferring pharmaceuticals, such as spanlastics, have emerged as an encouraging approach to overcome some of the difficulties. This article examines some of the critical factors that decide the performance of spanlastics formulations, for example, the ability to enhance bioavailability by improving the uptake of the drug within the eye's front and back regions. Further, the sustained release properties of spanlastics are discussed, which may significantly reduce the dosage periodicity, thereby, compliance from the patients is improved. The review also discusses targeted delivery of the drug through surface modification or conjugation of targeting ligands such that linezolid is delivered with improved accuracy to the site of infection, thus improving benefits of therapy while minimizing widespread negative impacts. Conclusion In this review, the possibility of linezolid-loaded spanlastics in treating the increasing issue of antibiotic resistance in ocular infections is presented. Advanced formulations with increased stability, targeted delivery, and improved patient compliance can be the future prospects of this novel drug delivery system, which can be a promising solution that allows for overall successful management regarding numerous types of sight ailments.

20 March 2025 in Biocatalysis and Agricultural Biotechnology
Verified
Journal Article
Closed access
AYAlinaj Yasin
Alinaj Yasin
BDBhaskar Dowarah
Bhaskar Dowarah
RBRosie Brahma
Rosie Brahma
RCRijubanki Challam
Rijubanki Challam
CBChayanika Bora
Chayanika Bora
ANURAG KASHYAPANURAG KASHYAP
ANURAG KASHYAP

15 November 2025 in Bioprinting
Verified
Journal Article
Closed access
ADAmit Kumar Das
Amit Kumar Das
AAAkramul Ansary
Akramul Ansary
BSBhargab Jyoti Sahariah
Bhargab Jyoti Sahariah
NBNilutpal Sharma Bora
Nilutpal Sharma Bora

1 January 2026 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DKDeepika Khatiwara
Deepika Khatiwara
SSSwapnaneel Sarma
Swapnaneel Sarma
MPManjyoti Pathak
Manjyoti Pathak
SSShourav Sangroula
Shourav Sangroula
BSBhargab Jyoti Sahariah
Bhargab Jyoti Sahariah
ADAmit Kumar Das
Amit Kumar Das

14 April 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
SSSwapnaneel Sarma
Swapnaneel Sarma
ADAmit Kumar Das
Amit Kumar Das
DKDeepika Khatiwara
Deepika Khatiwara
CBChayanika Bordoloi
Chayanika Bordoloi
MDManoj Kumar Deka
Manoj Kumar Deka
BSBhargab Jyoti Sahariah
Bhargab Jyoti Sahariah
Febuxostat is a selective xanthine oxidase inhibitor that is taken to manage gout; it has low aqueous solubility and unpredictable oral bioavailability. This paper examined amorphization induced by nanosponge incorporated in a sodium alginate transdermal system to achieve localized delivery of systems into the body. Emulation-solvent diffusion was used to prepare febuxostat-loaded nanosponges which were optimized with response surface methodology. The optimized formula had a particle size of 245.3 nm and entrapment efficiency of 77. Differential scanning calorimetry established a decrease of melting enthalpy of 92.4 J/g (pure drug) to 24.6 J/g, that is, a reduction of crystallinity by 73.4%. X-ray-diffraction of powdered material indicated a reduction of 66.04 in the amount of the peak at 33.96 crystallinity, which is indicative of amorphization. The patch loading nanosponge exhibited unburst continuous in vitro release (70.58% at 24 h). The release obeyed the first-order kinetics (R 2 = 0.9905) with a Korsmeyerexponent (n = 0.9954), which was anomalous diffusion. Ex vivo permeation analysis revealed steadiest flux of 0.2302, -g/cm 2/min (R 2=0.9986) and permeability coefficient of 0.04426 cm/min. Pharmacokinetic analysis in Wistar rats detected Cmax of 19,761.6ng/mL at Tmax of 24h, elimination half-life of 13.02h, AUC0-infty of 573,383 ng.h/mL, and MRT of 33.77h, which confirms the long systemic exposure. Stability tests showed that there was no major disturbance in the physicochemical whether in the accelerated conditions. These results define a structure-property-performance correlation that shows that solid-state conversion aided by nanosponge with diffusion under controlled by the matrix permits the delivery of poorly soluble drugs over an extended period by transdermal delivery.

25 March 2026 in Anti-Infective Agents
Verified
Journal Article
Closed access
PDF file
BMBanshongdor H. Mawlieh
Banshongdor H. Mawlieh
DKDeepika Khatiwara
Deepika Khatiwara
ADAmit Kumar Das
Amit Kumar Das
BSBhargab Jyoti Sahariah
Bhargab Jyoti Sahariah
MDManoj Kumar Deka
Manoj Kumar Deka
Introduction: Monkeypox (Mpox) is a zoonotic disease caused by the monkeypox virus (MPXV) with no approved antivirals. Smallpox vaccines have been used as preventive measures; however, supplies are limited and unreliable for post-exposure protection. Methodology: A comprehensive 15-year review (2008–2025) identified advances in vesicular nano formulation for monkeypox therapy, including marine-derived agents and nanoparticle delivery systems, revealing enhanced efficacy and mechanistic insights for targeted treatment. Thus, the progress in drug development and nanoparticle-mediated delivery strategies has been summarised in this paper. Results: Sophisticated tools, such as next-generation sequencing (NGS), real-time PCR, and whole-genome sequencing (WGS), significantly enhance monkeypox surveillance and diagnosis, while portable diagnostic devices, such as CRISPR-based assays and LAMP, enable point-of-care testing. Advanced imaging techniques, including photoacoustic microscopy, offer high-resolution, non-invasive visualisation of MPXV. Discussion: To overcome current challenges in monkeypox management, integrating innovative drug delivery systems and advanced analytical technologies with nanotechnology, particularly a microneedle-mediated delivery system, may improve the effectiveness of monkeypox treatments. Conclusion: Advances in diagnostics, surveillance, and nanotechnology are reshaping how we detect and manage the disease, but sustained control requires international collaboration, crossdisciplinary research, and improved access to healthcare resources to build long-term global health resilience.